Lung Adenocarcinoma with Pulmonary Miliary Metastases and Complex Somatic Heterozygous EGFR Mutation.

Date publication

septembre 2014

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BEAU-FALLER Michèle , Dr MENNECIER Bertrand

Tous les auteurs :
Schaller A, Beau-Faller M, Mennecier B, Renaud-Picard B, Weingertner N, Massard G, Quoix E

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/25722667

Résumé

The pretreatment detection of an activating mutation of EGFR is now routinely performed in metastatic nonsquamous non-small cell lung cancer (NSCLC). The therapeutic impact of such a detection is major, as patients with advanced NSCLC exhibiting a mutation of exon 19 or 21 will benefit from EGFR-tyrosine kinase inhibitors (TKI). The presence of an EGFR resistance mutation, such as T790M in EGFR-TKI-naive patients, is seldom looked for and is related either to a germinal mutation or to somatically mutated subclones. It has a negative predictive impact. We present the case of a patient with a lung papillary adenocarcinoma and miliary intrapulmonary metastases whose tumor displays a somatic complex heterozygous EGFR mutation, combining L858R (exon 21) and a primary resistance mutation T790M (exon 20), both detected by direct sequencing.

Référence

Case Rep Oncol. 2014 Nov 19;7(3):769-73